|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Necessity and indications of invasive treatment for Budd-Chiari syndrome显示文摘BACKGROUND:The development of collaterals in Budd-Chiari syndrome has been described and these collaterals play an important role in the presentation of this disease.These collaterals are diagnostic and their use in management strategy has never been evaluated.This study aimed to investigate the indications,feasibility and necessity of invasive treatment for patients with Budd-Chiari syndrome and to determine whether such a strategy is necessary for optimal management.METHODS:Twenty-nine patients who had been treated at our unit were enrolled in this study.Based on physical and biochemical examination,and hemodynamic compensation by collaterals,18 patients underwent radiological intervention (group A),while the other 11 had no invasive treatment (group B).The related hemodynamic parameters were acquired when percutaneous angiography was performed.RESULTS:In group A,all patients underwent successfully inferior vena cava (IVC) balloon angioplasty with or without stenting.Four patients also underwent hepatic vein angioplasty.In these patients,the mean IVC pressure before and after treatment was statistically different (29.3±9.2 vs 15.1±4.6 mmHg,P<0.01).The mean IVC pressure was much lower in group B than in group A (12.9±2.4 vs 29.3±9.2 mmHg,P<0.01),but there was no difference from that of the patients after radiological treatment (12.9±2.4 vs 15.1±4.6 mmHg,P>0.05).Median follow-up was 32.3 months (mean 21.3 months;range 3-61 months).In the course of follow-up,the patients in group A survived with good systemic status except for re-stenosis in one patient who underwent re-canalization of the IVC.In group B,10 patients had good systemic status except one patient who had a meso-caval shunt because of deterioration.CONCLUSIONS:The rationale of 'early diagnosis and early treatment' is not suitable for all patients with Budd-Chiari syndrome.Satisfactory survival can be achieved in some patients without invasive treatment,who are completely compensated by rich collaterals.Nonetheless,a positive treatment procedure should be performed if the patient's situation worsens in the course of regular follow-up. | Department of General Surgery (Fu Y,Sun YL,Ma XX,Xu PQ,Feng LS,Tang Z and Luo CH),Institute of Hepatic Vascular Disease (Sun YL),Department of Radiological Intervention (Guan S and Wang ZW),First Affiliated Hospital,Zhengzhou University School of Medicine,Zhengzhou 450052,China | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，3： | 10 |
| 2 | Surgical treatment of 1360 cases of Budd-Chiari syndrome:20-year experience显示文摘 | Xu PQ Ma XX Ye XX | 2004 | Hepatobil Pancreat Dis Int2004，3，3： | 1 |
| 3 | Simultaneous determination of oxiracetam and its degraded substance in rat plasma by HPLC-MS /MS and its application to pharmacokinetic study after a single high-dose intravenous administration 显示文摘 | Wan XH Wang H Ma PQ | 2014 | J Chromatogr B Analyt Technol Biomed Life Sci2014，969，： | 1 |
| 4 | Surgical treatment of 1360 cases of Budd-Chiari syndrome:20-year experience显示文摘 | Xu PQ Ma XX Ye XX | 2004 | Hepatobil Pancreat Dis Int2004，3，3： | 1 |
| 5 | Surgical treatment of 1360 cases of Budd-Chiari syndrome: 20- year experience 显示文摘 | Xu PQ Ma XX Ye XX | 2004 | Hepatobil Pancreat Dis Int2004，3，3： | 1 |
| 6 | Surgical treatment of 1360 cases of BucldChiari syndrome:20-year experience显示文摘 | Xu PQ Ma XX Ye XX | 2004 | Hepatobil Pancreat Dis Int2004，3，3： | 1 |
| 7 | Surgical treatment of 1360 cases of Budd- Chiari syndrome :20- year experience 显示文摘 | Xu PQ Ma XX Ye XX | 2011 | Hepatobil Pancre- at DisInt2011，3，3： | 1 |
| 8 | The Development and marketing predicition on the new anti diabetic drugs 显示文摘 | Ma PQ | 2005 | Prog Pharm Sci2005，29，8： | 1 |
| 9 | Surgical treatment of 1360 cases of Budd-Chiari syndrome:20-year experience显示文摘 | Xu PQ Ma XX Ye XX | 2004 | Hepatobil Pancreat Dis Int2004，3，3： | 1 |
| 10 | Progress in clinical application of paclitaxel显示文摘 | Ma PQ | 2004 | China Med Guide2004，6，3： | 1 |
| 11 | Surgical treatment of 1 360 cases of Budd-chiari syndrome:20-year experience显示文摘 | Xu PQ Ma XX Ye XX | 2004 | Hepatobiliary Pancreat Dis Int2004，3，3： | 1 |
| 12 | Spatio temporal analyses of highly pathogenic avian influenza H5N1 outbreaks in the Mekong River Delta, Vietnam, 2009 显示文摘 | Minh PQ Stevenson MA Jewell C | 2011 | Spatial and spatio - temooral eoidemiology2011，2，1： | 1 |
| 13 | Surgical treatment of 1 360cases of Budd-Chiari syndrome:20-year experience显示文摘 | Xu PQ Ma XX Ye XX | 2004 | Hepatobiliary Pancreat Dis Int2004，3，3： | 1 |
| 14 | Surgical treatment of 1360 cases of Budd-Chiari syndrome:20-year experience显示文摘 | Xu PQ Ma XX Ye XX | 2004 | Hepatobiliary Pancreat Dis Int2004，3，3： | 1 |
| 15 | Water-soluble phenylpropanoid constituents from aerial roots of Ficus microcarpa 显示文摘 | Ouyang MA Chen PQ Wang SB | 2007 | J Nat Prod2007，21，9： | 1 |
| 16 | Surgical treatment of 1 360 cases of Budd-Chiari syndrome:20-year experience显示文摘 | Xu PQ Ma XX Ye XX | 2004 | Hepatobiliary Pancreat Dis Int2004，3，3： | 1 |
| 17 | Stereoselective synthesis of D-α-glucopyranosides,di-and tri-saccharides via 6-O-acetyl-glucopyranosyl bromides显示文摘Acetyl bromide cleaved 2,3,4-tri-O-benzyl-l,6-anhydro-B-D-glucopyranose (la) or 2,3,4-tri-O-benzyl-1,6-anhydro-B-Z)-galactopyranose (1a’) to give the corresponding a-D-pyranosyl bromides (2). Reaction of 2 with ROH/diisopropylethylamine gave the corresponding a-glucopyra-nosides, di- and tri-saccharides with good yield. It was available to use 13C NMR to monitor the glycosidation reaction. | FEI, Chang-Pei MA, YueInstitute of Chemistry, Chinese Academy of Science, Beijing 100080, ChinaCHAN, Tak-HangDepartment of Chemistry, McGill University, Montreal, PQ, Canada | 1995 | Chinese Journal of Chemistry1995，13，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员